Main Causes of Tigecycline Shortage
Tigecycline, sold as Tygacil by Pfizer, faced U.S. shortages primarily due to manufacturing disruptions and quality issues at the Irish facility of Mylan (now part of Viatris), which produced the drug's active ingredient. In 2023, the FDA flagged sterility problems during an inspection, leading to a voluntary recall and halted production. Pfizer, the sole supplier, couldn't quickly ramp up output elsewhere, creating a nationwide gap.[1][2]
Demand spiked amid rising infections like complicated intra-abdominal and skin infections, where tigecycline serves as a last-resort antibiotic for multidrug-resistant bugs such as Acinetobacter and CRE. Hospital use surged post-COVID, exacerbating supply strain.[3]
How Long Has the Shortage Lasted?
The shortage began in early 2023 and persisted into 2024, with FDA logs showing resolved status for some lots by mid-2024 but ongoing allocation for others. Full recovery took over a year, as alternative sites came online slowly.[2][4]
Which Hospitals or Regions Felt It Worst?
Critical care units and ICUs in the U.S. hardest hit, especially in areas with high antibiotic resistance like the Southeast. Globally, similar issues cropped up in Europe via EMA alerts. No widespread international export from Pfizer filled the void quickly.[3][5]
What Alternatives Did Doctors Use?
Clinicians shifted to comparable tetracyclines like eravacycline (Xerava) or older options such as minocycline, though efficacy varies against tigecycline's spectrum. IV colistin or newer agents like plazomicin filled gaps for resistant cases, but with higher toxicity risks.[1][6]
Is Supply Back to Normal Now?
As of late 2024, FDA lists Tygacil as resolved in the U.S., with Pfizer confirming normalized distribution after qualifying new manufacturing. Watch for future risks from single-supplier dependency.[2][4]
Could Patents or Pricing Play a Role?
No direct patent link—core tigecycline patents expired in 2021—but limited generic entry due to manufacturing complexity prolonged vulnerability. Pricing stayed stable at ~$1,000 per 50mg vial, not a reported driver.[7]
[1]: FDA Drug Shortages Database
[2]: FDA Update on Tigecycline Shortage
[3]: CDC Antibiotic Resistance Threats Report
[4]: Pfizer Supply Statement
[5]: EMA Medicine Shortages
[6]: IDSA Guidance on Alternatives
[7]: DrugPatentWatch.com - Tigecycline Patents